C07D311/92

Method for the preparation of Intermediates for carboxy-fluoresceins and novel carboxy-fluorescein

The invention provides a method for the preparation of regioisomerically pure intermediates which are useful for the preparation of carboxy-fluorescein-type compounds. Such compounds have broad applications within bio-conjugation and/or fluorescent imaging.

Method for the preparation of Intermediates for carboxy-fluoresceins and novel carboxy-fluorescein

The invention provides a method for the preparation of regioisomerically pure intermediates which are useful for the preparation of carboxy-fluorescein-type compounds. Such compounds have broad applications within bio-conjugation and/or fluorescent imaging.

SELECTIVE PHOSPHATASE INHIBITORS BASED ON ILLUDALIC ACID

The present disclosure provides novel selective phosphatase inhibitor compounds based on illudalic acid. The present disclosure provides a streamlined method of synthesizing illudalic acid and a method for synthesizing phosphatase inhibitor compounds. The method of this invention provides convergent benzannulation of β-keto amides and esters, followed by a one-pot reduction/hydrolysis sequence. The concise synthetic approach provided by this invention enables rapid assembly of illudalog compounds of this invention that are potent protein tyrosine phosphatase receptor-type D (PTPRD) inhibitors.

SELECTIVE PHOSPHATASE INHIBITORS BASED ON ILLUDALIC ACID

The present disclosure provides novel selective phosphatase inhibitor compounds based on illudalic acid. The present disclosure provides a streamlined method of synthesizing illudalic acid and a method for synthesizing phosphatase inhibitor compounds. The method of this invention provides convergent benzannulation of β-keto amides and esters, followed by a one-pot reduction/hydrolysis sequence. The concise synthetic approach provided by this invention enables rapid assembly of illudalog compounds of this invention that are potent protein tyrosine phosphatase receptor-type D (PTPRD) inhibitors.

NAPHTHOPYRAN-CONTAINING COMPOUND, POLYMER, MIXTURE, COMPOSITION AND USE THEREOF IN WATER-SOLUBLE PHOTOCHROMIC MATERIALS
20230265066 · 2023-08-24 ·

Provided herein are a series of water-soluble photochromic naphthopyran compounds, a mixture and a polymer thin film comprising the same, and applications thereof in photochromic materials, especially water-soluble photochromic material. The present photochromic naphthopyran compounds display excellent water solubility in neutral pH environment, rapid light response and fast thermal bleaching.

NAPHTHOPYRAN-CONTAINING COMPOUND, POLYMER, MIXTURE, COMPOSITION AND USE THEREOF IN WATER-SOLUBLE PHOTOCHROMIC MATERIALS
20230265066 · 2023-08-24 ·

Provided herein are a series of water-soluble photochromic naphthopyran compounds, a mixture and a polymer thin film comprising the same, and applications thereof in photochromic materials, especially water-soluble photochromic material. The present photochromic naphthopyran compounds display excellent water solubility in neutral pH environment, rapid light response and fast thermal bleaching.

MEDICINAL USE OF SERRULATANE DITERPENES

The present disclosure is drawn to methods of treating diseases or disorders, and uses of preparing medicaments. The methods of administering and/or preparation of medicaments can include the use of a compound of Formula (I) disclosed herein, or a geometric isomer, stereoisomer, and/or pharmaceutically acceptable salt or solvate thereof.

HETEROCYCLYL POLYMETHINE IR CHROMOPHORES

The present disclosure provides NIR- and SWIR-active small molecule polymethine dyes with improved properties for use in optical imaging, photothermal therapy, and photodynamic therapy.

HETEROCYCLYL POLYMETHINE IR CHROMOPHORES

The present disclosure provides NIR- and SWIR-active small molecule polymethine dyes with improved properties for use in optical imaging, photothermal therapy, and photodynamic therapy.

COMPOUND AS PPAR AGONIST AND APPLICATION THEREOF
20230322692 · 2023-10-12 · ·

The present invention provides compounds as PPAR agonists and their application, involving a new class of peroxisome proliferator-activated receptor (PPAR) gamma receptor agonist, which can inhibit the production of mitochondrial reactive oxygen species, and most of which can readily cross the blood-brain barrier. The present invention also includes pharmaceutical uses of the compounds.